221 related articles for article (PubMed ID: 23748853)
1. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.
Eichelser C; Flesch-Janys D; Chang-Claude J; Pantel K; Schwarzenbach H
Clin Chem; 2013 Oct; 59(10):1489-96. PubMed ID: 23748853
[TBL] [Abstract][Full Text] [Related]
2. Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
Stückrath I; Rack B; Janni W; Jäger B; Pantel K; Schwarzenbach H
Oncotarget; 2015 May; 6(15):13387-401. PubMed ID: 26033453
[TBL] [Abstract][Full Text] [Related]
3. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.
Eichelser C; Stückrath I; Müller V; Milde-Langosch K; Wikman H; Pantel K; Schwarzenbach H
Oncotarget; 2014 Oct; 5(20):9650-63. PubMed ID: 25333260
[TBL] [Abstract][Full Text] [Related]
4. Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
Lehmann TP; Korski K; Gryczka R; Ibbs M; Thieleman A; Grodecka-Gazdecka S; Jagodziński PP
Mol Med Rep; 2015 Sep; 12(3):4692-4702. PubMed ID: 26130254
[TBL] [Abstract][Full Text] [Related]
5. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer.
Zeng Z; Chen X; Zhu D; Luo Z; Yang M
Yonsei Med J; 2017 Jul; 58(4):697-702. PubMed ID: 28540980
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients.
Niedźwiecki S; Piekarski J; Szymańska B; Pawłowska Z; Jeziorski A
Ginekol Pol; 2018; 89(8):415-420. PubMed ID: 30215459
[TBL] [Abstract][Full Text] [Related]
7. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.
Anfossi S; Giordano A; Gao H; Cohen EN; Tin S; Wu Q; Garza RJ; Debeb BG; Alvarez RH; Valero V; Hortobagyi GN; Calin GA; Ueno NT; Woodward WA; Reuben JM
PLoS One; 2014; 9(1):e83113. PubMed ID: 24416156
[TBL] [Abstract][Full Text] [Related]
8. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer.
Asaga S; Kuo C; Nguyen T; Terpenning M; Giuliano AE; Hoon DS
Clin Chem; 2011 Jan; 57(1):84-91. PubMed ID: 21036945
[TBL] [Abstract][Full Text] [Related]
9. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
10. Underexpression of circulating miR-145-5p and miR-133a-3p are associated with breast cancer and immunohistochemical markers.
García-Magallanes N; Beltran-Ontiveros SA; Leal-León EA; Luque-Ortega F; Romero-Quintana JG; Osuna-Ramirez I; Barbosa-Jasso M; Arámbula-Meraz E
J Cancer Res Ther; 2020; 16(6):1223-1228. PubMed ID: 33342777
[TBL] [Abstract][Full Text] [Related]
11. Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer.
Li J; Song ZJ; Wang YY; Yin Y; Liu Y; Nan X
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706621
[TBL] [Abstract][Full Text] [Related]
12. MiR-34a modulates ErbB2 in breast cancer.
Wang Y; Zhang X; Chao Z; Kung HF; Lin MC; Dress A; Wardle F; Jiang BH; Lai L
Cell Biol Int; 2017 Jan; 41(1):93-101. PubMed ID: 27813227
[TBL] [Abstract][Full Text] [Related]
13. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer.
Yang L; Feng Y; Qi P; Xu S; Zhou Y
J Biol Regul Homeost Agents; 2016; 30(4):1041-1045. PubMed ID: 28078851
[TBL] [Abstract][Full Text] [Related]
15. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic factors associated with de novo metastatic breast cancer.
Shen T; Siegal GP; Wei S
Pathol Res Pract; 2016 Dec; 212(12):1167-1173. PubMed ID: 27692496
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients.
Schwarzenbach H; Milde-Langosch K; Steinbach B; Müller V; Pantel K
Breast Cancer Res Treat; 2012 Aug; 134(3):933-41. PubMed ID: 22350790
[TBL] [Abstract][Full Text] [Related]
19. Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients.
Ni Q; Stevic I; Pan C; Müller V; Oliveira-Ferrer L; Pantel K; Schwarzenbach H
Sci Rep; 2018 Aug; 8(1):12974. PubMed ID: 30154547
[TBL] [Abstract][Full Text] [Related]
20. Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.
Sakurai M; Masuda M; Miki Y; Hirakawa H; Suzuki T; Sasano H
Int J Biol Markers; 2015 May; 30(2):e190-9. PubMed ID: 25907662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
